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Abstract
Introduction: Multi-drug-resistant tuberculosis (MDR-TB) has emerged as a challenge to global tuberculosis (TB) control
and remains a major public health concern in many countries. Diabetes mellitus (DM) is an increasingly recognized
comorbidity that can both accelerate TB disease and complicate its treatment. The aim of this study is to summarize
available evidence on the association of DM and MDR-TB among TB patients and to provide a pooled estimate of risks.
Methods: All studies published in English before October 2016 will be searched using comprehensive search strings
through PubMed, EMBASE, Web of Science, and WHO Global Health Library databases which have reported the
association of DM and MDR-TB in adults with TB (age > =15). Two authors will independently collect detailed
information using structured data abstraction form. The quality of studies will be checked using Newcastle-Ottawa Scale
for cohort and case-control studies and the Agency for Healthcare Research and Quality tool for cross-sectional studies.
Heterogeneity between included studies will be assessed using the I2 statistic. We will check potential publication bias
by visual inspection of the funnel plot and Egger’s regression test statistic. We will use the random effects model to
compute a pooled estimate.
Discussion: Increases in the burden of non-communicable diseases and aging populations are changing the
importance of different risk factors for TB, and the profile of comorbidities and clinical challenges for people with TB.
Although classic risk factors and comorbidities such as overcrowding, under-nutrition, silicosis, and HIV infection are
crucial to address, chronic conditions like diabetes are important factors that impair host defenses against TB. Thus,
undertaking integrated multifaceted approach is remarkably necessary for reducing the burden of DM and successful TB
treatment outcome.
Systematic review registration: PROSPERO CRD42016045692.
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Introduction
Multi-drug-resistant tuberculosis (MDR-TB) has emerged
as a challenge to global tuberculosis (TB) control and re-
mains a major public health concern in many countries. It
is an infectious disease caused by strains of mycobacterium
TB that are resistant to at least isoniazid and rifampicin [1].
Drug-resistant TB has been reported since the early days of
the introduction of anti-TB chemotherapy [2].
In the year 2014, an estimated 3.3% of new cases and
20% of previously treated TB cases have MDR-TB [3].
The eastern European and central Asian countries have
the highest levels of MDR-TB. For example, estimated
new TB cases with MDR-TB were 34% in Belarus and
26% in both Kazakhstan and Kyrgyzstan [3]. Similarly,
the estimated re-treatment TB cases with MDR-TB were
as high as 69% in Belarus and 58% in Kazakhstan [3].
Globally in 2014, 190,000 deaths occurred due to MDR-
TB. It is also estimated that 99,000 cases of MDR-TB
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emerge every year, of which 62,000 were among notified
cases of TB in 2014 [3].
The emergence of multi-drug resistance across the
world poses a global threat as the treatment is difficult,
expensive, and a major health care cost burden to devel-
oping countries [4]. Most cases of MDR-TB are arising
from a mixture of physician error, inadequate and
incomplete treatment, and patient non-compliance dur-
ing treatment of susceptible TB [5, 6]. The international
community has responded with financial and scientific
support, leading to new rapid diagnostics, new drugs,
and regimens in advanced clinical development [7].
Diabetes mellitus (DM) is an increasingly recog-
nized comorbidity that can both accelerate TB disease
and complicate TB treatment. The prevalence of DM
among TB patients around the world varies according
to different regions that range from 12 to 44% and
tended to increase in the past decade [8]. It increases
the risk of TB disease, complicates TB treatment, and
increases the risk of a poor TB outcome [9, 10].
Among MDR-TB patients, DM is a relatively common
comorbidity [11]. In addition to the well-established
contribution of DM to enhanced TB risk, there is
growing evidence from observational studies that this
comorbidity is associated with delays in mycobacter-
ium TB clearance during treatment, treatment fail-
ures, death, relapse and re-infection [12]. However,
whether DM presents any additional risk for the
development or acquisition of MDR-TB remains
controversial [13–15]. Three case-control studies
comparing DM/TB and non-diabetic TB patients from
Iran, Saudi Arabia, and Turkey showed no significant
association between DM and the risk of MDR-TB [16–18].
Similarly, cross-sectional studies in Iran, Turkey, and
Taiwan have reported no association between DM and
MDR-TB [19–21]. On the other hand, many studies have
found 2.1 to 8.8 times increased the risk of MDR-TB
among diabetic TB patients [22–26]. In addition, observa-
tional studies from Israel, Georgia, and Mexico have also
shown patients with DM had a higher risk of developing
MDR-TB [27–29].
Similarly, none of the systematic reviews and meta-
analysis conducted so far [10, 11, 22, 30–36] has
addressed DM associated risk of developing MDR-TB.
Thus, further meta-analysis and synthesis of the avail-
able evidence is needed now. This systematic review
and meta-analysis will be done to identify gaps on
whether there is a risk of MDR-TB associated with DM
and provide the necessary evidence to design (inter)-
national policy guidelines for the management of MDR-
TB. Hence, the current study aims to summarize avail-
able evidence on the association of DM and MDR-TB




Our systematic review has been registered with the
International Prospective Register of Systematic Reviews
(PROSPERO) (http://www.crd.york.ac.uk/PROSPERO/dis-
play_record.asp?ID=CRD42016045692; registration number
CRD42016045692). This protocol is written in accord-
ance with recommendations from the Preferred Reporting
Items for Systematic Review and Meta-Analysis Protocols
(PRISMA-P) 2015 statement [37] and the PRISMA-P
checklist has been completed (see Additional file 1).
Results will be reported based on the PRISMA state-
ment guideline [38, 39].
Eligibility criteria
We will include all observational studies (cross-sectional,
case-control, cohort, survey, and surveillance reports)
which have reported the association of DM and MDR-
TB in adults with TB (age > =15). All studies published
in English before October 2016 will be reviewed as well.
Data source and search strategy
PubMed, Excerpta Medica Database(EMBASE), Web of
Science, and WHO Global Health Library databases will
be searched for all publications. We will also search
bibliographies of identified articles and gray literature. In
addition, authors will be contacted and requested for
additional information in case of missing data. In
consultation with an experienced medical information
specialist, comprehensive search strategy has been
developed (see Additional file 2).
Study selection
Articles will be screened and selected for full-text review
if they met the following selection criteria: (1) they
provided or permitted the computation of an effect esti-
mate of DM on the development of MDR-TB among TB
patients. (2) They included TB patients (all type) and
defined MDR-TB based on standard protocols. (3) They
defined DM as any of the following: baseline diagnosis
by self-report, medical records, laboratory test, or treat-
ment with oral hypoglycemic medications or insulin. We
will exclude studies for any of the following reasons:
citations without abstracts; anonymous reports; dupli-
cate studies; case reports or studies which did not com-
pare MDR-TB among people with DM to people
without DM; systematic reviews and meta-analysis. Also,
studies in which people with DM received different anti-
TB treatment regimens than people without DM and
studies that either did not provide effect estimates in
odds ratios, rate ratios, hazard ratios, or relative risks or
did not allow for the computation of these values will be
excluded. Two reviewers will screen and check full-text
studies for inclusion independently. Any disagreements
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will be resolved by discussion between the two reviewers.
If consensus could not be reached, a third reviewer
will determine the eligibility and approve the final list
of retained studies.
Data extraction and quality assessment
Structured data abstraction form will be constructed and
pre-tested. For every study that met our eligibility cri-
teria, two investigators (BS and TD) independently will
extract the title, name of authors, year of publication,
country, study design, study population, sample size,
data collection procedure, diagnosis of DM, and MDR-
TB, adjustment for potential confounders, effect sizes
with 95% confidence intervals and proportion of TB-
diabetic patients who developed MDR. Search results
will be compiled using citation management software
(RefWorks 2.0; ProQuest LLC, Bethesda, Maryland,
USA, http://www.refworks.com). The same authors (BS
and TD) will check the quality of studies independently
using Newcastle-Ottawa Scale (NOS) [40] for cohort
and case-control studies and the Agency for Healthcare
Research and Quality (ARHQ) [41] tool for cross-
sectional studies. Disagreement will be resolved by
consensus. In case of persistent disagreement a third
reviewer will be consulted.
Data synthesis and statistical analysis
Review Manager (RevMan) version 5.3.5 (Cochrane In-
formatics and Knowledge Management Department) for
Windows [42] will be used for analysis. Heterogeneity be-
tween included studies will be assessed using the I2 statis-
tic described by Higgins et al. with I2 from 75 to 100%
suggesting considerable heterogeneity [43].We will check
potential publication bias by visual inspection of the fun-
nel plot. Besides, Egger’s regression test will be used to
statistically check the asymmetry of the funnel plot [44].
Publication bias will be assumed P value less than 0.10.
Original studies will be described using study charac-
teristics summary table and forest plot. A meta-analysis,
to compute a pooled estimate, will be performed if vari-
ability among studies is low. However, if the pooling of
data is not feasible due to heterogeneity, we will descrip-
tively report the results of each study. Odds ratio will be
used as a measure of overall association between DM
and MDR-TB. We will meta-analyze estimates with simi-
lar sets of confounds. Presuming the variation of the
true effect of DM on MDR-TB for different populations,
we will use the random effects model and weighting
method [45]. Subgroup analysis and meta-regression will
be performed for types of DM and types of TB.
Discussion
Increases in the burden of non-communicable diseases
and aging populations are changing the importance of
different risk factors for TB. Although classic risk factors
and comorbidities such as overcrowding, undernutrition,
silicosis, and HIV infection are crucial to address,
chronic conditions like diabetes are important factors
that impair host defenses against TB [46].
The association of diabetes and TB was confirmed by
Root since 1934 [47]. So far, many types of research and
reviews have confirmed this finding and suggest that the
overall risk of TB in persons with DM is two to three
times higher than in the general population [10, 46, 48].
DM in this association may still contribute substantially
to the burden of TB and negatively affect the treatment
outcome. Chronic hyperglycemia at least to some extent
may alter the treatment outcome and prognosis of TB
[49]. Several studies have been conducted to assess the
association between MDR-TB and DM in different
regions of the world [13, 15–17, 22]. However, these
studies did not provide consistent evidence on whether
DM has an increased risk for MDR-TB. Therefore, this
systematic review and meta-analysis aim to provide a
pooled estimate on the risk of DM for developing
MDR-TB.
Clinicians and researchers should generate the neces-
sary evidence for improvements to patient services and
policies on combined TB and diabetes [50]. Our review
will clarify the existing controversies on whether DM
puts the higher risk for MDR-TB. Hence, the results of
this review will be helpful to remove confusions for
policy-makers, clinicians, and patients and it might be
helpful to undertake integrated approach for reducing
the burden of DM on successful TB treatment outcome.
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